The sensitivity of collagen-induced platelet aggregation to aspirin was measured in vitro on platelet-rich plasma from 20 normal subjects and five patients with von Willebrand's disease. Although aspirin tolerance tests performed in vivo at the same time showed an abnormal prolongation of the bleeding time in three of the patients studied, no evidence was found for an enhanced sensitivity to aspirin in vitro. Quick (1966) showed that aspirin increases the bleeding time in normal subjects, and this increase is accentuated in patients with various bleeding disorders (Beaumont, Willie, and Lenfgre, 1955a).
SYNOPSIS
The sensitivity of collagen-induced platelet aggregation to aspirin was measured in vitro on platelet-rich plasma from 20 normal subjects and five patients with von Willebrand's disease. Although aspirin tolerance tests performed in vivo at the same time showed an abnormal prolongation of the bleeding time in three of the patients studied, no evidence was found for an enhanced sensitivity to aspirin in vitro. Quick (1966) showed that aspirin increases the bleeding time in normal subjects, and this increase is accentuated in patients with various bleeding disorders (Beaumont, Willie, and Lenfgre, 1955a) . Weiss and Aledort (1968) showed impaired interaction between platelets and connective tissue in vivo in man after the ingestion of aspirin. This inhibitory effect has also been demonstrated in vitro by Evans (1967) . If platelet aggregation induced by collagen were abnormally sensitive to the inhibitory effect of aspirin in patients with bleeding disorders, it might suggest a mechanism by which this inordinate prolongation of the bleeding time occurs. This hypothesis has been tested in the following investigation.
Materials
'Collagen' was prepared by partly homogenizing human Achilles tendon and suspending the homogenate in 0 05 M Tris buffer, pH 7-2, at 21°C, with filtration through coarse nylon mesh. The suspension was centrifuged at 17,000g, the supernatant discarded, and the sediment resuspended in Tris. The process was repeated three times. The final suspension was stored at -20°C in 0 5 ml aliquots after rapid freezing at -78°C. 
Subjects
Normal subjects consisted of laboratory and medical staff, none of whom had a history of bleeding disorder. All the patients with von Willebrand's disease had a clear history of haemostatic defect and affected close relatives of both sexes. In addition, each patient had on at least one occasion in the past been found to have a bleeding time of more than 10 minutes and a factor VIII level of less than 45 %. Subjects were not tested until at least 10 days had elapsed since they last ingested aspirin. Platelet aggregation tests could not reproducibly be performed on subjects with peripheral blood platelet counts of less than 150,000/cmm, so that these were excluded from the study. Born (1962) . Platelet-rich plasma was dispensed in 0-48 ml aliquots into a series of tubes containing magnetic stirrers covered with silicone rubber. Either Tris buffer or aspirin solution (0-06 ml) was added to each tube and the mixtures were incubated for exactly 10 minutes at 370C. Then 0-06 ml of collagen suspension was blown in and aggregation curves were recorded. For each subject, aggregation curves were obtained in response to two concentrations of collagen. At each strength of collagen, the effect of preincubation of platelet-rich plasma with Tris buffer and two different concentrations of aspirin was observed. A value for the rate of aggregation of each mixture was obtained by measuring the change in light transmission per unit time when aggregation was in its most rapid phase. Tests were replicated following a balanced design to eliminate the effect of spontaneous changes in the activity of reagents as discussed by Cox (1951) .
Results

BLEEDING TIME EXPERIMENTS
These were performed on 10 normal subjects and six patients with von Willebrand's disease. The ingestion of 600 mg of aspirin in normal subjects produced a significant mean rise in the bleeding time of 1 5 min (Table I) . Placebo tablets produced no significant difference in the bleeding time. Table I also compares the effect of aspirin or placebo in normal subjects with that of aspirin in patients. As can be seen, three of the patients (nos. 1, 4, and 5) showed a response to aspirin markedly in excess of the normal range.
PLATELET AGGREGATION STUDIES
The Figure shows dose-response results obtained from a normal subject. It will be seen that the degree of inhibition was related to the concentration of aspirin in the reaction mixture. The degree of inhibition of the collagen activity may be calculated in such a parallel-line bioassay and expressed as the 'relative collagen activity' (Table  II) . Values for relative collagen activity were calculated for patients and normal subjects. The mean difference in bleeding time after placebo was not significant (SE diff = 0-429, t 0-58, df = 18, P > 0 3), but the mean difference two hr after the ingestion of aspirin was significant (SE diff = 0-155, t = 10-16, df = 18, P < 0-001). The difference between the mean aspirin and the mean placebo effect, ie, the difference between the differences, was also significant (SE diff between diffs -0356, t = 3-47, df = 36, P > 0-0025). These SEs are derived from the pooled between-subjects variance of bleeding time results before and after placebo or aspirin in the 10 normal subjects (homogeneous by Bartlett's test: x' = 3-897, df = 3, 0 3> P > 0-2), with the appropriate aliowances for covariance. (Spaet and Zucker, 1964) and probably also by lysed red cells (Rorvik, Holmsen, and Stormorken, 1968) . Aspirin has been shown to inhibit the release of ADP by platelets (Weiss, Aledort, and Kochwa, 1968) rather than the response to platelets to ADP, and Beaumont et al (1955b) 
